Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $19.75.

Several analysts have recently issued reports on the company. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Wells Fargo & Company set a $18.00 price objective on Satellos Bioscience in a research note on Thursday, July 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Friday, August 7th. HC Wainwright upped their target price on Satellos Bioscience from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Finally, Canaccord Genuity Group raised Satellos Bioscience to a “moderate buy” rating in a research report on Thursday, May 21st.

Satellos Bioscience Price Performance

Shares of NASDAQ:MSLE opened at $9.82 on Friday. The company has a market capitalization of $204.65 million, a PE ratio of -6.14 and a beta of 1.51. Satellos Bioscience has a 1 year low of $4.84 and a 1 year high of $13.39. The stock has a fifty day simple moving average of $8.13.

Satellos Bioscience (NASDAQ:MSLE) last posted its earnings results on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.18). On average, equities analysts anticipate that Satellos Bioscience will post -1.69 earnings per share for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.